Insulin glargine: Long-acting basal insulin analog for improved metabolic control

Current Medical Research and Opinion

Volumn 20, Issue 1, 2004, Pages 31-37

  Gerich, John E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Basal insulin; Insulin glargine; Pharmacokinetics

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONAL REGULATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN;

EID: 0346724642     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002711     Document Type: Review

References (27)

1. Anderson JHJ, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997;157:1249-55
2. Anderson JH, Jr., Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R for the Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997;46:265-70
3. Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999;22:468-77
4. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22:1501-6
5. Nobels FR, Hermans MP, De Leeuw I. Insulin lispro (Humalog®), a novel fast-acting insulin analogue: guidelines for its practical use. Acta Clin Belg 1999;54:246-54
6. Texas Diabetes Council. Insulin algorithm for type 2 diabetes mellitus in children and adults. Available from http://www.tdh.state.tx.us/diabetes/pdf/algorithms/inst2.pdf. [Accessed 16 September 2003]
7. Del Sindaco P, Ciofetta M, Lalli C, et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 1998;15:592-600
8. Rizza RA, Gerich JE, Haymond MW, Westland RE, Hall LD, Clemens AH, Service FJ. Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy. N Engl J Med 1980;303:1313-18
9. Zinman B. The physiologic replacement of insulin. An elusive goal. N Engl J Med 1989;321:363-70
10. Bolli GB, De Feo P, De Cosmo S, et al. Demonstration of a dawn phenomenon in normal human volunteers. Diabetes 1984;33:1150-3
11. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990;13:923-54
12. Heinemann L. Hypoglycemia and insulin analogues: is there a reduction in the incidence? J Diabetes Complications 1999;13:105-14
13. Bolli GB, Gottesman IS, Campbell PJ, et al. Glucose counterregulation and waning of insulin in the Somogyi phenomenon (posthypoglycemic hyperglycemia). N Engl J Med 1984;311:1214-19
14. Hirsch IB. Intensive treatment of type 1 diabetes. Med Clin North Am 1998;82:689-719
15. Galloway JA, Chance RE. Insulin agonist therapy: a challenge for the 1990s. Clin Ther 1990;12:460-72
16. 125I-insulin absorption and blood glucose concentration. Diabetologia 1979;17:291-5
17. B32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997;320:259-65
18. Rosenstock J, Schwartz SL, Clark CM, Jr., et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6
19. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8
20. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9
21. Ratner RE, Hirsch IB, Mecca TE, Wilson CA. Efficacy and safety of insulin glargine in subjects with type 1 diabetes: a 28 week randomized, NPH insulin-controlled trial. Diabetes 1999;48(Suppl 1):A120
22. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA for the US Study Group of Insulin Glargine in Type 1 Diabetes. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-43
23. Pieber TR, Eugene-Jolchine I, Derobert E for the European Study Group of HOE 901 in Type 1 Diabetes. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000;23:157-62
24. Raskin P, Klaff L, Bergenstal R, Halle J-P, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-71
25. Rosenstock J, Park G, Zimmerman J for the US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000;23:1137-42
26. Yki-Järvinen H, Dressler A, Ziemen M for the HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-6
27. Riddle MC, Rosenstock J, Gerich J on behalf of the Insulin Glargine 4002 Study Investigators. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):forthcoming